Stephanie E Combs1,2. 1. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Ismaninger Straße 22, 81675, Munich, Bavaria, Germany. Stephanie.Combs@tum.de. 2. Institute of Innovative Radiotherapy (iRT), Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Bavaria, Germany. Stephanie.Combs@tum.de.
Abstract
BACKGROUND: Novel techniques in radiation oncology have significantly improved the therapeutic window in locally advanced pancreatic cancer LAPC. In about one third of the patients, chemoradiation can lead to secondary resectability, contributing to an increase in outcome. Dose-escalation approaches using stereotactic body radiotherapy (SBRT) or advanced treatments such as intensity-modulated radiotherapy (IMRT) can exploit the biological benefits of hypofractionation, or use "dose painting" approaches to target defined subvolumes. Prognostic subgroups of patients have been identified, based on molecular markers such as CA 19-9, nutritional factors, diabetes or immunological properties of tumor and normal tissue. PURPOSE: The aim of the present manuscript is to summarize data on downsizing for locally advanced pancreatic cancer (LAPC) and to elucidate the role of individualized radiotherapy (iRT). CONCLUSION: Future concepts focus on iRT based on prognostic factors leading to a true personalized treatment.
BACKGROUND: Novel techniques in radiation oncology have significantly improved the therapeutic window in locally advanced pancreatic cancer LAPC. In about one third of the patients, chemoradiation can lead to secondary resectability, contributing to an increase in outcome. Dose-escalation approaches using stereotactic body radiotherapy (SBRT) or advanced treatments such as intensity-modulated radiotherapy (IMRT) can exploit the biological benefits of hypofractionation, or use "dose painting" approaches to target defined subvolumes. Prognostic subgroups of patients have been identified, based on molecular markers such as CA 19-9, nutritional factors, diabetes or immunological properties of tumor and normal tissue. PURPOSE: The aim of the present manuscript is to summarize data on downsizing for locally advanced pancreatic cancer (LAPC) and to elucidate the role of individualized radiotherapy (iRT). CONCLUSION: Future concepts focus on iRT based on prognostic factors leading to a true personalized treatment.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Leah M Ferrucci; Diana Bell; Jennifer Thornton; Glenda Black; Ruth McCorkle; Douglas C Heimburger; Muhammad Wasif Saif Journal: Support Care Cancer Date: 2010-10-22 Impact factor: 3.603
Authors: Jerome Landry; Paul J Catalano; Charles Staley; Wayne Harris; John Hoffman; Mark Talamonti; Natalie Xu; Harry Cooper; Al B Benson Journal: J Surg Oncol Date: 2010-06-01 Impact factor: 3.454
Authors: Daniel Richter; Christian Graeff; Oliver Jäkel; Stephanie E Combs; Marco Durante; Christoph Bert Journal: Radiother Oncol Date: 2014-11-25 Impact factor: 6.280
Authors: Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni Journal: J Gastrointest Surg Date: 2008-03-18 Impact factor: 3.452
Authors: Daniel Richter; Nami Saito; Naved Chaudhri; Martin Härtig; Malte Ellerbrock; Oliver Jäkel; Stephanie E Combs; Daniel Habermehl; Klaus Herfarth; Marco Durante; Christoph Bert Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-01 Impact factor: 7.038
Authors: Stephanie E Combs; Daniel Habermehl; Kerstin A Kessel; Frank Bergmann; Jens Werner; Patrick Naumann; Dirk Jäger; Markus W Büchler; Jürgen Debus Journal: Ann Surg Oncol Date: 2014-06-11 Impact factor: 5.344